🔗 Visit the ClinicalTrials.gov page for NCT00831480
| Rank | Title | Journal | Year | PubWeight™‹?› |
|---|---|---|---|---|
| 1 | Biomarkers: the next therapeutic hurdle in metastatic renal cell carcinoma. | Br J Cancer | 2012 | 0.88 |
| 2 | Functional imaging of renal cell carcinoma. | Nat Rev Urol | 2010 | 0.84 |
| 3 | Everolimus: the first approved product for patients with advanced renal cell cancer after sunitinib and/or sorafenib. | Biologics | 2010 | 0.83 |
| 4 | Clinical experience with everolimus in the second-line treatment of advanced renal cell carcinoma. | Ther Adv Urol | 2015 | 0.75 |
| 5 | Future directions of mammalian target of rapamycin (mTOR) inhibitor therapy in renal cell carcinoma. | Target Oncol | 2011 | 0.75 |